ReadCoor

company

About

Leader in true multi-omic spatial sequencing

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$23M
Industries
Biotechnology,Medical,Pharmaceutical
Founded date
Sep 1, 2016
Number Of Employee
11 - 50
Operating Status
Active

ReadCoor is a technology company offering the first true spatial multi-omic platform to the global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and to facilitate the creation of new therapeutics for patients. The company’s RC2 Platform simultaneously detects and reads the sequences of tens to thousands of RNA, DNA, proteins, and therapeutics and visualizes sub-cellular nanoscale 3D resolution in every cell throughout any tissue section. The Platform, based on ReadCoor’s proprietary Fluorescent in situ Sequencing (FISSEQ) technology, combines the massive multiplexity of next-generation sequencing (NGS) and high-resolution tissue imaging.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$50M
ReadCoor has raised a total of $50M in funding over 2 rounds. Their latest funding was raised on Jan 10, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 10, 2020 Series B $27M 1 Pavilion Capital Detail
Sep 29, 2016 Series A $23M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
ReadCoor is funded by 2 investors. Pavilion Capital and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Pavilion Capital Yes Series B
Lilly Asia Ventures Series A